


7th CACHEXIA CONFERENCE



KOBE/OSAKA JAPAN

9-11 December 2013

Abstract submissions are welcome

- ▶ Deadline September 30, 2013
- ▶ Poster presentation
- ▶ Poster awards
- ▶ Young investigator awards
- ▶ Plenty of time for discussion

For further information visit
www.cachexia.org



Monday, December 9, 2013

13:30 - 15:30 - OPENING SESSION

Muscle Wasting – Assessment & Epidemiology

“Hippocrates” clinical science key note lecture: Assessing muscle mass – brief history and state of the art

Stephen Heymsfield, Baton Rouge, USA

Muscle mass and survival: the epidemiologic viewpoint

Kamyar Kalantar-Zadeh, Los Angeles, USA

Psychosocial effect of cachexia

Jane Hopkinson, Cardiff, UK

Frailty: international consensus and its role in sarcopenia and cachexia

John E Morley, St. Louis, USA

The obesity paradox in 2013 – the stroke example

Wolfram Doehner, Berlin, Germany

15:30 - 16:00 - Coffee break

16:00 - 17:45 - PLENARY SESSION

Muscle Wasting – New Therapeutic Approaches

“Prometheus” basic science key note lecture:

Ghrelin – from discovery to therapy

Masayasu Kojima, Kurume, Japan

Targeting MIC-1/GDF1

Samuel Breit, Sydney, Australia

Muscle regeneration & miRNAs

Thomas Thum, Hannover, Germany

Biomarkers for skeletal muscle wasting – international consensus

Emanuele Marzetti, Rome, Italy

18:00 - 19:15 - Welcome reception and poster viewing

Tuesday, December 10, 2013

07:15 - 08:15 - Sponsored breakfast seminars

08:30 - 10:00 - CLINICAL TRACK

Skeletal muscle mass & chronic illness

New methods to assess skeletal muscle mass changes

William Evans, Research Triangle Park, USA

The interface between fat and muscle in late life sarcopenia & cachexia

Tamara Harris, Bethesda, USA

Cachexia in CHF and COPD: similarities and differences

Annemie Schols, Maastricht, the Netherlands

Respiratory muscles mass and function & COPD exacerbation

Mike Polkey, London, UK

Muscle wasting, exercise and hip fracture

Maria Fiatarone Singh, Sydney, Australia

Why are so many companies studying inclusion body myositis?

08:30 - 10:00 - BASIC TRACK

From food intake to ghrelin and sarcopenia

Alterations in the Ghrelin/NPY axis in anorexia and cachexia

Herbert Herzog, Sydney, Australia

Etanercept for cachexia in rheumatoid arthritis: roles of gut hormones and leptin

Chih-Yen Chen, Taipei, Taiwan

The herbal medicine rikkunshito in cancer anorexia-cachexia: impact

on survival and relationship to ghrelin signaling

Akihiro Asakawa, Kagoshima, Japan

Modulation of hunger and satiety peptide activity by plasma immunoglobulins

Serguei Fetissov, Rouen, France

Sarcopenic obesity

Kyung Mook Choi, Seoul, Korea

10:00 - 11:00 - Coffee break & poster sessions

11:00 - 12:30 - BASIC TRACK

Muscle basic science

Signaling pathways that mediate sarcopenia and cachexia – 2013 update.

The mitochondrial contribution to muscle atrophy in aging and disease

Yi-Fan Chen, Taichung, Taiwan

The role of differentiation as causal factor in cancer-induced muscle wasting

Denis Guttridge, Columbus, USA

Proteolysis mechanisms – an update

Didier Attaix, Clermont-Ferrand, France

Muscle and non-muscle tissue interactions in cachexia:

the role of inflammation

Josep Argiles, Barcelona, Spain

Panel discussion «Perspectives of research»

11:00 - 12:30 - CLINICAL TRACK

Oncology and cancer cachexia

Impact of cancer cachexia on oncology outcomes and anticancer treatment

Florian Strasser, St. Gallen, Switzerland

Multi-modal therapy for a multimodal problem: the MENAC study

Ken Fearon, Edinburgh, UK

Diagnostic criteria of cancer cachexia: a critical evaluation

Vickie Baracos, Edmonton, Canada

Cardiovascular problems and autonomic dysfunction in cancer cachexia

Jochen Springer, Berlin, Germany

Nutritional intervention in cancer cachexia

Nicolaas Deutz, College Station, USA

12:45 - 13:45 - Sponsored lunch seminars

14:00 - 15:30 - CLINICAL TRACK

Drug treatment options and results update

SARMs

Ghrelin

Targeting myostatin & activin receptors

Novel beta-blockers

Panel discussion

14:00 - 15:30 - JUDGES' CHOICE

Oral presentations of selected abstracts

15:30 - 16:30 - Coffee break and poster sessions

16:30 - 18:00 - CLINICAL TRACK

Late breaking clinical trials and biomarker research

16:30 - 18:00 - BASIC TRACK

Metabolic syndrome, biomarkers and body wasting

Cachexia in chronic kidney disease

Robert Mak, La Jolla, USA

Muscle wasting in diabetes

Antonio Zorzano, Barcelona, Spain

Diabetes mellitus and muscle wasting

Seok Won Park, Seoul, Korea

New biomarkers for skeletal muscle wasting in chronic illness

Stephan von Haehling, Berlin, Germany

Brown fat in cachexia

Graham Robertson, Concord, Australia

19:30 - CONFERENCE DINNER

Wednesday, December 11, 2013

08:00 - 09:30 - Young investigators Awards Session - Clinical & Basic

3 basic science and 3 clinical research presentations to be short-listed

08:00 - 09:30 - CLINICAL & BASIC TRACKS

Food intake, appetite and nutrition

Effects of melatonin on appetite and other symptoms in cancer cachexia

Edigio Del Fabbro, Richmond, USA

Screening questionnaires for malnutrition and sarcopenia

Ted Malmstrom, St. Louis, USA

Mechanisms of anorexia

Johan Ruud, Linköping, Sweden

Anorexia and quality of life

Alessandro Laviano, Rome, Italy

Nutrition in drug trials – problems & opportunities

Jürgen Bauer, Nuremberg, Germany

09:30 - 10:30 - Coffee break & poster sessions

10:30 - 12:00 - JUDGES' CHOICE

Oral presentations of selected abstracts (clinical & nutrition science)

10:30 - 12:00 - BASIC TRACK

Central mechanisms of cachexia

Rodent models of cachexia: predict power for clinical trials

Daniel Marks, Portland, USA

The role of the brain stem: autonomic dysfunction

Massimo Piepoli, Piacenza, Italy

Central mechanisms of appetite & fatigue

John E Morley, St. Louis, USA

Abnormal reflex systems in cachexia

Ewa Jankowska, Wroclaw, Poland

12:15 - 13:15 - Sponsored lunch seminars

13:30 - 15:00 - PLENARY SESSION

Developing therapies for cachexia & sarcopenia

The role of blood based biomarkers for muscle wasting treatment trials

Marc Hellerstein, Berkeley, USA

Remote monitoring of body weight, fluid status and physical activity:

telemedicine for cachexia & sarcopenia?

Friedrich Köhler, Berlin, Germany

What should usual care for nutrition be in cachexia trials?

Aminah Jatoi, Rochester, USA

What are approvable endpoints in cachexia & sarcopenia?

Stefan Anker, Berlin, Germany

The regulators comments

Giuseppe Rosano, London, UK

Panel discussion

15:00 - 15:30 - Coffee break

15:30 - 16:30 - PLENARY SESSION

Congress highlights

Basic Science

Denis Guttridge, Columbus, USA

Sarcopenia

Mitja Lainscak, Golnik, Slovenia

Nutritional Therapies

Maurizio Muscaritoli, Rome, Italy

Treatment of cachexia

Andrew Coats, Melbourne, Australia

AWARDS CEREMONY